Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lifestance Health (LFST)

LifeStance Q3 revenue rises 16% to $363.8 million; raises Adjusted EBITDA outlook

Positive Impact 4 of 5 earnings Written later

LifeStance reported third-quarter 2025 results on November 6, 2025, with revenue of $363.8 million, up 16% from a year earlier, and net income of $1.1 million compared with a net loss of $6.0 million in the prior-year quarter. The company raised its full-year 2025 Adjusted EBITDA guidance to $146 million to $152 million and raised the midpoint of its Center Margin expectations, while reiterating its full-year revenue outlook of $1.41 billion to $1.43 billion.

Key points

  • Q3 2025 revenue of $363.8 million, up 16%; clinician base rose 11% to 7,996.
  • Net income of $1.1 million versus a $6.0 million net loss a year earlier; Adjusted EBITDA of $40.2 million, up 31%.
  • Full-year 2025 Adjusted EBITDA guidance raised to $146 million to $152 million; revenue guidance reiterated at $1.41 billion to $1.43 billion.
  • Fourth-quarter 2025 outlook: total revenue of $368 million to $388 million and Adjusted EBITDA of $37 million to $43 million.

The filing

CompanyLifestance Health (LFST)
Form8-K, current report
Filed with the SECNov 5, 2025, 6:41 PM ET
Accession number0001193125-25-267443

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.